Dyne治疗机构报告2025年损失更大,审判结果良好,现金跑道延长到2028年。 Dyne Therapeutics reported a larger 2025 loss, positive trial results, and extended cash runway into 2028.

Dyne治疗公司报告说,2025年Q4净损失为1.12亿美元,即每股0.76美元,比上一年大,研发费用增至9 540万美元。 Dyne Therapeutics reported a Q4 2025 net loss of $112 million, or $0.76 per share, wider than the prior-year period, with R&D expenses rising to $95.4 million. 该公司在2025年结束时的现金为11亿美元,预计资金将持续到2028年初。 The company ended 2025 with $1.1 billion in cash and expects funds to last into early 2028. 它在日本获得Z-Basivarsen的孤儿药物指认,报告在Duchenne肌肉萎缩区对Z-Rostudisen的DELIVER第1/2阶段试验取得正面的顶级结果,并完成了公开发行1 898万股。 It received orphan drug designation for Z-basivarsen in Japan, reported positive topline results from its Phase 1/2 DELIVER trial of Z-Rostudirsen in Duchenne muscular dystrophy, and completed a public offering of 18.98 million shares.